CDLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cardlytics Inc (CDLX) is not a good buy at the moment for a beginner investor with a long-term strategy. The company's financial performance is weak, with significant declines in revenue, net income, and EPS. Analysts have lowered price targets, and the stock is in 'show me' territory. While hedge funds are increasing their positions, insider selling and the absence of strong proprietary trading signals suggest caution. The technical indicators do not provide a clear entry point, and the stock's future price trend appears uncertain.
The MACD is positive and expanding, indicating potential bullish momentum. However, the RSI is neutral, and moving averages are converging, suggesting no strong trend. The stock is trading near its pivot point of 0.893, with resistance at 1.089 and support at 0.697.
The sale of the Bridg business simplifies operations and provides PAR Technology equity, which could be monetized. Hedge funds are significantly increasing their positions.
Insiders are selling heavily. Financial performance is deteriorating, with YoY declines in revenue, net income, and EPS. Analysts have lowered price targets, citing challenges such as the BofA exit and Bridg divestiture.
In Q4 2025, revenue dropped by -24.19% YoY to $56.1M. Net income fell by -47.08% YoY to -$8.25M, and EPS decreased by -51.61% YoY to -$0.15. Gross margin also declined slightly by -3.28% YoY to 45.45%.
Analysts have lowered their price targets recently. Evercore ISI reduced the target to $1 from $2, maintaining an In Line rating. Lake Street lowered the target to $1.25 from $1.50, maintaining a Hold rating. Analysts believe the stock is in 'show me' territory, reflecting near-term challenges.
